Colon cancer vaccine trials 2012

Landenberger Research Foundation. The Alfred W. The Department specifically disclaims responsibility for any analyses, interpretations or conclusions.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Article reference: Adam E. Snook, Trevor R. Baybutt, Bo Xiang, Tara S. Abraham, John C. Kraft, Takami Sato and Scott A. Media contact: Edyta Zielinska edyta. As of September 1, , the study was expanded to a total of 6 arms the original 3 arms A, B, C and 3 additional arms which were the same as the first 3 but with cetuximab in treating patients who have undergone surgery for stage III colon cancer.

Drugs used in chemotherapy, such as irinotecan hydrochloride, fluorouracil, leucovorin calcium, and oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.

The primary purpose of this study is to collect de-identified, clinically-characterized stool and whole blood specimens for use in developing and evaluating the performance of new biomarker assays for the detection of colorectal cancer CRC.

The purpose of this study is to obtain longitudinal information on four sub-populations from the Cologuard Post-Approval Study. The sub-populations consist of the following characteristics: positive first Cologuard test and negative colonoscopy or no colonoscopy and positive 3-year follow-up Cologuard test and negative colonoscopy or no colonoscopy.

The purpose of this study is to survey the Native Americans and their medical providers from two upper midwest communities for their perceptions about colon cancer, and the benefits or barriers for screening. The purpose of this study is to measure the quality and quantity of the lifespan in patients who have locally recurrent rectal cancer.

It will compare survival rates and quality of life of those who have surgery to those who do not have surgery. It also aims to compare certain other factors, such as whether clear resection margins i. PRI is a new investigational drug being studied to treat subjects with cancer who have advanced solid tumors.

PRI is thought to work by blocking the Wnt signaling pathway that cancer cells need to grow and spread metastasize. Phase Ia: Patient cohorts with solid tumor malignancies will be treated with escalating doses per cohort of PRI in order to identify the MTD of this single-agent regimen.

Patient cohorts with CRC will be The purpose of this study is to assess the relationship between lifetime and recent alcohol consumption history and disease free survival in a population of stage III colon cancer patients treated with chemotherapy and curative surgical resection. It is not yet known whether giving This randomized phase III trial studies oxaliplatin, leucovorin calcium, fluorouracil, and bevacizumab to see how well they work compared to oxaliplatin, leucovorin calcium, and fluorouracil in treating patients who have undergone surgery for stage II colon cancer.

Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving combination Evaluate decision-making satisfaction and decisional conflict surrounding the use of K-ras molecular testing to enhance cancer management. Identify educational needs and preferences of patients to enhance use of molecular testing for cancer treatment decision-making. The purpose of this study is to develop a health services registry and repository to prospectively examine patient use of health services and related health outcomes over time among a cohort of adults who have had an order placed for Cologuard.

This phase II trial studies how well Polyphenon E works in treating patients with high-risk of colorectal cancer. Polyphenon E contains ingredients that may prevent or slow colorectal cancer. The purpose of this research study is to see if cancer will respond better to a combination of irinotecan and cetuximab with or without bevacizumab.

To study intestinal permeability in participants with stage 3 colon cancer before and during chemotherapy and compare with controls with normal colon, chronic ulcerative colitis CUC and carcinoid syndrome.

To study the correlation between intestinal permeability and symptoms severity during 5-FU chemotherapy. To study the correlation between intestinal permeability and neutrophils to lymphocytes ratio NLR before and during chemotherapy. To analyze the changes in expression levels of genes encoding intercellular junction proteins in all groups.

To determine if diarrhea in participants with carcinoid syndrome is associated with increasedintestinal permeability. The investigators hypothesize that spraying peppermint oil containing L-menthol onto the colonic mucosa during colonoscopy will relax smooth muscle allowing better colonic visualization.

This randomized phase III trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid DNA mismatch repair. Drugs used in combination chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy with atezolizumab may work better The purpose of this study is to assess the long term clinical outcomes of patients who had a false positive stool DNA test for colorectal cancer. The main objective of this study is to test the safety and effectiveness of DSa for participants with HER2-expressing advanced colorectal cancer.

The purposes of this study are to characterize the microbes that are causal of colorectal cancer and those that are merely conditions of the tumor. This will be accomplished by comparing the microbiomes before and after resection.

Secondly, to pilot a study to differentiate between the effect of resection versus the effect of tumor removal by comparing microbiomes in two cohorts: colorectal cancer patients and controls from benign colon resection.

Finally, to understand what confers community-level microbial stability or resilience in a colorectal cancer patient. This pilot study will be accomplished by sampling stool samples from patients longitudinally, and then using advance This randomized phase II trial studies how well irinotecan hydrochloride and cetuximab with or without vemurafenib works in treating patients with colorectal cancer that has spread to nearby tissue or lymph nodes, that has spread to other places in the body, or cannot be removed by surgery.

Irinotecan hydrochloride and vemurafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, may block the ability of tumor cells to grow and spread. It is not yet known whether irinotecan hydrochloride and cetuximab are more effective with or without The primary purpose of this study is to assess the sensitivity for colorectal cancer CRC and specificity of the mt-sDNA 2.

This randomized phase I trial studies the side effects and best dose of linaclotide acetate in preventing colorectal cancer in healthy volunteers.

The use of linaclotide acetate may prevent colorectal cancer. The study is an open-label, dose escalation clinical trial to evaluate the safety, tolerability, and PK of fruquintinib in patients with advanced solid tumors.

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon cancer. This randomized phase II trial studies how well lower-dose compared to standard dose regorafenib works in treating patients with colorectal cancer that has spread from the primary site place where it started to other places in the body and does not respond to treatment.

Regorafenib may stop the growth of colorectal cancer by blocking the growth of new blood vessels necessary for tumor growth and by blocking some of the enzymes needed for cell growth. It is not yet known whether lower-dose or standard dose regorafenib is more effective in treating patients with colorectal cancer. Clobetasol propionate is a steroid The purpose of this study is to compare the effectiveness and safety of fruquintinib plus best supportive care BSC versus placebo plus BSC in patients with refractory metastatic colorectal cancer mCRC.

Approximately subjects will be randomized to one of the following treatment arms in a ratio, fruquintinib plus BSC or placebo plus BSC.

This study will assess the efficacy and outcomes of PD-1 blockade in patients with mismatch repair deficient colorectal cancer. The purpose of the study is to measure high grade toxicity of regorafenib and to monitor the impact of treatment with regorafenib on the quality of life in older adults with metastatic colorectal cancer. The purpose of this study is to investigate the combination of standard of care treatment of TAS and the experimental peptide vaccine, PolyPEPI, to learn more about the side effects of combination and to collect information on how cancer responds to this combination.

T cells fight infections and can also kill cancer cells. The effectiveness and safety of TheraSphere will be evaluated in patients with colorectal cancer with metastases in the liver, who are scheduled to receive second line chemotherapy. All patients receive the standard of care chemotherapy with or without the addition of TheraSphere. The purpose of this study is to find out if ginseng decreases fatigue in people who were treated for cancer.

The purose of this study is to determine how well binimetinib and palbociclib work compared to TAS in treating patients with KRAS and NRAS mutation positive colorectal cancer that has spread to other places in the body or cannot be removed by surgery.

Binimetinib and palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as TAS, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving binimetinib and palbociclib The purpose of this study is to evaluate the clinical activity, safety and tolerability of etruma-based treatment combinations.

The primary objective of this study is to collect de-identified, clinically-characterized stool and whole blood specimens for use in developing and evaluating the performance of new biomarker assays for detection of colorectal cancer CRC.

This is a blinded study such that the Investigator and Subject will be blinded but AbbVie will be unblinded. This randomized phase II trial studies how well atezolizumab and capecitabine with or without bevacizumab work in treating patients with colorectal cancer that is not responding to treatment and has spread to other places.

Monoclonal antibodies, such as atezolizumab and bevacizumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

If you continue to get this message, reach out to us at customer-service technologyreview. Skip to Content. Colon cancer: This x-ray image shows a barium enema in a patient with cancer of the bowel. Keep Reading. Most Popular. Deepfake researchers have long feared the day this would arrive. By Karen Hao archive page. By Charlotte Jee archive page. By Lucas Laursen archive page. By Tanya Basu archive page. Stay connected Illustration by Rose Wong.